Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Nateglinide 120 mg

Nateglinide 120 mg was supplied as tablets.

DRUG

Acarbose 50 mg

Acarbose 50 mg was supplied as tablets.

Trial Locations (6)

100020

People's Liberation Army. The Military General Hospital of BeiJing, Beijing

100034

Peiking University First Hospital, Beijing

100853

Chinese PLA General Hospital, Beijing

510080

The First Affiliated Hospital, Zhongshan (Sun Yat-sen) University, Guangzhou

510120

The Second Affiliated Hospital, Zhongshan (Sun Yat-sen) University, Guangzhou

510515

Nanfang Hospital, the Affiliated South Hospital of the Southern Medical University, Guangzhou

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY